About
BliNK Biomedical develops B cell–based antibody discovery technology using validated platforms ISAAC and VIVA|Screen to identify and isolate very rare antibody-secreting cells from humans and other species for therapeutic antibody discovery.
Explore BliNK Biomedical's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.